Notably, transferrin receptor (TfR)-targeted NPs, including T7-functionalized PLGA NPs, achieve approximately sixfold increases in brain delivery, with measurable improvements in therapeutic outcomes in stroke and glioma models. This evidence concerns the gene TFRC and central nervous system cancer.